- Cytotoxic Constituents from the Roots of Asarum sieboldii in Human Breast Cancer Cells
-
Kim E, Kim HJ, Oh HN, Kwak AW, Kim SN, Kang BY, Cho SS, Shim JH, Yoon G
- KMID: 2443107
- Nat Prod Sci.
- 2019 Mar;25(1):72-75.
- doi: 10.20307/nps.2019.25.1.72
Bioassay-guided fractionation of the roots of Asarum sieboldii led to the isolation of the six compounds methylkakuol (1), sesamin (2), asarinin (3), xanthoxylol (4), and (2E,4E,8Z,10E/Z)-N-(2-methylpropyl) dodeca-2,4,8,10-tetraenamide (5/6). Among the... -
- CITED
-
- Close
- SHARE
-
- Close
- 3-Deoxysappanchalcone Inhibits Cell Growth of Gefitinib-Resistant Lung Cancer Cells by Simultaneous Targeting of EGFR and MET Kinases
-
Lee JY, Lee SO, Kwak AW, Chae SB, Cho SS, Yoon G, Kim KT, Choi YH, Lee MH, Joo SH, Park JW, Shim JH
- KMID: 2544067
- Biomol Ther.
- 2023 Jul;31(4):446-455.
- doi: 10.4062/biomolther.2023.070
The mechanistic functions of 3-deoxysappanchalcone (3-DSC), a chalcone compound known to have many pharmacological effects on lung cancer, have not yet been elucidated. In this study, we identified the comprehensive... -
- CITED
-
- Close
- SHARE
-
- Close
- Podophyllotoxin Induces ROS-Mediated Apoptosis and Cell Cycle Arrest in Human Colorectal Cancer Cells via p38 MAPK Signaling
-
Lee SO, Joo SH, Kwak AW, Lee MH, Seo JH, Cho SS, Yoon G, Chae JI, Shim JH
- KMID: 2522254
- Biomol Ther.
- 2021 Nov;29(6):658-666.
- doi: 10.4062/biomolther.2021.143
Podophyllotoxin (PT), a lignan compound from the roots and rhizomes of Podophyllum peltatum, has diverse pharmacological activities including anticancer effect in several types of cancer. The molecular mechanism of the... -
- CITED
-
- Close
- SHARE
-
- Close
- Picropodophyllotoxin Inhibits Cell Growth and Induces Apoptosis in Gefitinib-Resistant Non-Small Lung Cancer Cells by Dual-Targeting EGFR and MET
-
Lee JY, Kang BY, Jung SJ, Kwak AW, Lee SO, Park JW, Joo SH, Yoon G, Lee MH, Shim JH
- KMID: 2539589
- Biomol Ther.
- 2023 Mar;31(2):200-209.
- doi: 10.4062/biomolther.2022.113
Patients with non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) amplification or sensitive muta-tions initially respond to the tyrosine kinase inhibitor gefitinib, however, the treatment becomes less effective... -
- CITED
-
- Close
- SHARE
-
- Close
